Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?
about
Clinical review: Traumatic brain injury in patients receiving antiplatelet medicationSafety of a high bolus dose of tirofiban in patients undergoing coronary stent placementTherapeutic approaches in arterial thrombosisSame-day transradial outpatient stenting with a 6-hr course of glycoprotein IIb/IIIa receptor blockade: a feasibility studyPKCalpha regulates platelet granule secretion and thrombus formation in miceCoronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management.Use of glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST-elevation myocardial infarction.Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.Abciximab as an adjunctive therapy for patients undergoing percutaneous coronary interventions.Platelets are versatile cells: New discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond.Oral platelet glycoprotein IIb/IIIa inhibition.Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents.Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons?The use of the glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary intervention.Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECTIntegrin targeted therapeutics.Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment.Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents.Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitorInhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial.Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice.Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals.Future innovations in anti-platelet therapies.Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease.Platelet integrins and immunoreceptors.Use of stent grafts and coils in vessel rupture and perforation.Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban.Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: A review.The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy.Review of Currently Available GP IIb/IIIa Inhibitors and Their Role in Peripheral Vascular Interventions.Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.The platelet fibrinogen receptor: from megakaryocyte to the mortuary.Chrysoptin is a potent glycoprotein IIb/IIIa fibrinogen receptor antagonist present in salivary gland extracts of the deerfly.Anti-platelet therapy in small animal medicine.Why we need intravenous antiplatelet agents.Use of antiplatelet inhibitors in peripheral vascular interventions.RP-HPLC Method Development and Validation for Determination of Eptifibatide Acetate in Bulk Drug Substance and Pharmaceutical Dosage Forms.Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting.
P2860
Q26830409-E99CF2A6-58BC-4FFA-92FF-9A86E6DF44A1Q28167029-CD481326-4BDD-416E-A079-0C65B31A74CAQ28187576-A140EE58-0FB3-42D6-ADF1-2DED20BF1202Q28192874-5E5D0FC4-9F9F-47A3-9FEC-B52C950B687CQ28505136-5F3A8A43-11F9-413A-A251-1AB5231A3D25Q30658145-C401FC2D-60A0-419B-8BC5-4EAA7C773DD1Q33369310-2D44D785-273A-443C-926E-FC0608C7B104Q33386229-00A59C1A-E242-4CD1-8335-778C1562B8E5Q33393501-459C17D8-929A-4527-ACA2-B8FA1DF5EE68Q33432917-428BFDA9-6ABF-406F-821F-AA5271C64FD4Q34027516-44255472-5B52-440C-BEE9-82D0371CA847Q34027525-029AC4D1-2761-4D54-B351-6304399689C1Q34075194-616F857E-0BDF-4AD6-820B-91346B8FEE92Q34145163-DF5BC9F1-0544-4556-B37F-B5AB6ED250AEQ34675290-EEFC811C-D297-4571-9A65-FBCC618E7407Q34912643-6DEEF434-4974-463A-BFD6-48C7D364E61CQ34912684-F2D6E241-32CD-42DA-8937-5F1E94B2739DQ35008537-7E9387C3-708A-4370-B9ED-0FC6FEF7570BQ35152095-3F8ECD2A-C06F-4422-9F29-FA831DBE2761Q35750010-7B2ACA7B-6863-4E50-ADBE-5897C49479C9Q36151450-EEECB531-F892-41F8-924C-C694A6BA55ACQ36376147-93C7A75B-3A0F-48E2-9E03-8DC9DBE77DBDQ36634214-CC68E87D-1CDC-438B-B344-EA7129E776ABQ36753593-E2533F0D-0E3F-447B-B525-0FBA47298EE8Q36813106-624275A7-CBE7-4AF5-9E38-2F5FB3A7F0B3Q36877378-9BA25EAF-0A5C-4240-A405-DB630EDB545FQ37078402-D933096A-1AF1-4853-B0FB-84E8689C786CQ37385355-B60F5456-8F54-4B6C-A94E-6FCA7FA306FBQ37431543-2614B37A-0504-4F00-BE6B-32509C9C2676Q37604903-45F99EC1-F1C8-4FFA-89BF-E7176040B783Q38006947-1D2959FE-3371-47E8-BF0D-804DC0CA0A13Q38058760-CB342C4E-81B9-4CCE-8810-E9E4FB16B972Q38072598-08759184-3F9D-4689-B3C8-2163CA1918D6Q38156780-8942CD42-931F-4BBF-99F8-FC89D52DA14EQ38312064-4F945BED-4CA8-4122-AC44-2F110C66A9A0Q38770733-7250EC40-31EE-4033-A1DF-D44FF132AB3FQ38851769-1DC19A76-70CF-411B-B8F9-E7C32DBA09D2Q42118681-89B42083-087D-4CF5-B7DE-4153DA45E1FDQ42360543-DE4471B3-944F-4E37-B8F9-C5D891A2A8E7Q43002184-96180713-ED10-4F1E-BAC1-63056412DC63
P2860
Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Platelet glycoprotein IIb/IIIa ...... pharmacology and clinical use?
@ast
Platelet glycoprotein IIb/IIIa ...... pharmacology and clinical use?
@en
Platelet glycoprotein IIb/IIIa ...... pharmacology and clinical use?
@nl
type
label
Platelet glycoprotein IIb/IIIa ...... pharmacology and clinical use?
@ast
Platelet glycoprotein IIb/IIIa ...... pharmacology and clinical use?
@en
Platelet glycoprotein IIb/IIIa ...... pharmacology and clinical use?
@nl
prefLabel
Platelet glycoprotein IIb/IIIa ...... pharmacology and clinical use?
@ast
Platelet glycoprotein IIb/IIIa ...... pharmacology and clinical use?
@en
Platelet glycoprotein IIb/IIIa ...... pharmacology and clinical use?
@nl
P2093
P356
P1433
P1476
Platelet glycoprotein IIb/IIIa ...... pharmacology and clinical use?
@en
P2093
Kleiman NS
Phillips DR
Scarborough RM
P304
P356
10.1161/01.CIR.100.4.437
P407
P577
1999-07-01T00:00:00Z